Adobe: Analysts' Upgrades, Downgrades

NEW YORK (

TheStreet

) --

CHANGE IN RATINGS

Alkermes

(ALKS) - Get Report

reinstated at BofA/Merrill with a Buy rating and $16 price target. Untapped value in Vivitrol.

Cablevision

(CVC)

initiated at JPMorgan. Initiated with an Overweight rating and $30 price target. Introduces 2010 EPS estimates of $1.41.

DreamWorks

(DWA)

upgraded at Stifel from Hold to Buy. $35 price target. Stock appears oversold at current levels.

Edwards Lifesciences

(EW) - Get Report

downgraded at Goldman from Buy to Neutral. Stock was also cut from the Conviction List. Valuation call, based on a $60 price target.

Holly Corp

( HOC) upgraded at BofA/Merrill to Buy from Neutral. Valuation call. Price target jumped to $35 from $32.

Lululemon

(LULU) - Get Report

rated new Neutral at Baird. $49 price target. Stock is already pricing in the company's strong growth prospects.

MannKind

(MNKD) - Get Report

reinstated at BofA/Merrill with a Buy rating and $18 price target. Low expectations priced in.

Monster Worldwide

(MWW)

upgraded at Oppenheimer from Perform to Outperform. $21 price target. Fundamentals are bottoming and the company should benefit from a cyclical recovery in employment.

Niska Gas Storage

(NKA)

initiated at Credit Suisse with an Outperform rating and $21 price target. NKA is one of two pure-play natural gas storage MLPs.

Noranda Aluminum

(NOR)

initiated at Credit Suisse with an Outperform rating and $11 price target. NOR's dominant driver will be underlying aluminum prices.

Noranda Aluminum

(NOR)

initiated at BofA/Merrill with a Buy rating and $11 price target. High leverage to commodity price rebound.

PPL

(PPL) - Get Report

upgraded at Soleil from Hold to Buy. $29 price target. Earnings visibility should improve, following the company's recent acquisitions.

Treehouse Foods

(THS) - Get Report

rated new Equal-weight at Morgan Stanley. The company's organic growth prospects are in-line with its peers.

STOCK COMMENTS / EPS CHANGES

Adobe Systems

(ADBE) - Get Report

estimates increased at Goldman through 2012. Company is seeing better CS sales. Buy rating and $46 price target.

Adobe Systems

(ADBE) - Get Report

estimates upped at UBS through 2011. Company is seeing better sales. Buy rating and $45 price target.

Carnival

(CCL) - Get Report

price target cut at Credit Suisse to $38 from $40.50 following lackluster 2Q10 update. Maintain Neutral rating.

Carnival

(CCL) - Get Report

estimates increased at UBS through 2011. Company continues to see better demand. Buy rating and $43 price target.

Goldman Sachs

(GS) - Get Report

price target cut at Barclays. GS price target sunk to $175 from $195 on tougher financial market conditions. Estimates lowered through 2011. Maintain Equal Weight rating.

Jabil Circuit

(JBL) - Get Report

price target tweaked at Credit Suisse to $18 from $18.60 on great 3Q10 results, partly overshadowed by inventory. Leverage story ends, growth story begins. Maintain Neutral rating.

Jabil

(JBL) - Get Report

estimates, target raised at UBS. Shares of JBL now seen reaching $21. Estimates also increased, to match the company's new guidance for consumer-related growth. Buy rating.

L-3 Communications

(LLL) - Get Report

price target lower at Barclays to $100 from $114 on worries about future defense spending. Maintain Overweight rating.

Morgan Stanley

(MS) - Get Report

estimates cut at Barclays. MS 2010 and 2011 EPS estimates dropped to $2.83 and $3.25, respectively. Barclays noted wider credit spreads, higher volatility, and a flight to safety. Maintain Equal Weight rating and $34 price target.

Ralcorp

( RAH) estimates, target lowered at UBS. Shares of RAH now seen reaching $62, according to UBS. Estimates also cut, as the company continues to struggle in the cereal business. Neutral rating.

Union Pacific

(UNP) - Get Report

target upped at Morgan Stanley to $87. Volumes are trending higher across the board. Overweight rating.

Walgreen

(WAG)

target higher, estimates changed at Barclays. WAG price target raised to $29 from $27. WAG is struggling with Rx margins. 2010 EPS estimates reduced to $2.09, 2011 lifted to $2.36. Maintain Equal Weight rating.

Walgreen

(WAG)

estimates cut at Morgan Stanley through 2012. Company is facing lower margins, because of prescription reimbursement rates. Equal-weight rating.

This article was written by a staff member of TheStreet.com.